Should I buy or sell Xtant Medical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xtant Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XTNT shares. View XTNT analyst ratings or view top-rated stocks .

What is Xtant Medical's stock price target for 2024?

2 Wall Street analysts have issued twelve-month price targets for Xtant Medical's shares. Their XTNT share price targets range from $1.20 to $2.00. On average, they predict the company's stock price to reach $1.60 in the next year. This suggests a possible upside of 91.2% from the stock's current price. View analysts price targets for XTNT or view top-rated stocks among Wall Street analysts .

Are investors shorting Xtant Medical?

Xtant Medical saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 280,600 shares, an increase of 45.8% from the March 15th total of 192,500 shares. Based on an average daily trading volume, of 145,100 shares, the short-interest ratio is currently 1.9 days. Currently, 0.6% of the shares of the company are short sold. View Xtant Medical's Short Interest .

When is Xtant Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our XTNT earnings forecast .

How were Xtant Medical's earnings last quarter?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) released its earnings results on Wednesday, February, 24th. The medical device company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.11. The medical device company had revenue of $14.02 million for the quarter. Xtant Medical had a net margin of 0.72% and a trailing twelve-month return on equity of 1.56%.

When did Xtant Medical's stock split?

Shares of Xtant Medical reverse split before market open on Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What guidance has Xtant Medical issued on next quarter's earnings?

Xtant Medical issued an update on its FY 2024 earnings guidance on Monday, April, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $112.0 million-$116.0 million, compared to the consensus revenue estimate of $115.9 million.

What other stocks do shareholders of Xtant Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xtant Medical investors own include Aurinia Pharmaceuticals (AUPH) , LadRx (CYTR) , Heat Biologics (HTBX) , Neovasc (NVCN) , Rexahn Pharmaceuticals (REXN) , Biopharmx (BPMX) , Adamis Pharmaceuticals (ADMP) , Lipocine (LPCN) and Synergy Pharmaceuticals (SGYP) .

How do I buy shares of Xtant Medical?

Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:XTNT

Xtant Medical (XTNT) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free XTNT Stock Alerts

$0.84

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.80
▼
$0.90
50-Day Range: N/A
52-Week Range: $0.60
▼
$1.45

Volume: 123,193 shs
Average Volume: 146,567 shs
Market Capitalization: $108.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.60

Get Xtant Medical alerts:

Xtant Medical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 91.2% Upside
$1.60 Price Target
Short Interest: Healthy
0.62% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.04 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Xtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Xtant Medical has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.62% of the float of Xtant Medical has been sold short.
Short Interest Ratio / Days to Cover
Xtant Medical has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Xtant Medical has recently increased by 45.77%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Xtant Medical does not currently pay a dividend.
Dividend Growth
Xtant Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for XTNT.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Xtant Medical this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xtant Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.80% of the stock of Xtant Medical is held by insiders.
Percentage Held by Institutions
69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Xtant Medical has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Xtant Medical Stock (NYSEAMERICAN:XTNT)

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

XTNT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XTNT Stock News Headlines

April 19, 2024 | americanbankingnews.com

Xtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above Two Hundred Day Moving Average of $0.00

April 10, 2024 | americanbankingnews.com

Xtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above 200-Day Moving Average of $0.00

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 2, 2024 | finance.yahoo.com

Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2023 Earnings Call Transcript

April 2, 2024 | finance.yahoo.com

Q4 2023 Xtant Medical Holdings Inc Earnings Call

April 1, 2024 | investorplace.com

XTNT Stock Earnings: Xtant Medical Hldgs Misses EPS, Beats Revenue for Q4 2023

April 1, 2024 | finance.yahoo.com

Xtant Medical Holdings Inc (XTNT) Reports Record Revenue in 2023, Outpacing Analyst Estimates

April 1, 2024 | globenewswire.com

Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 30, 2024 | finance.yahoo.com

Xtant Medical Holdings, Inc. (XTNT)

March 28, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Trulieve Cannabis (TCNNF), Xtant Medical Holdings (XTNT)

March 21, 2024 | globenewswire.com

Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024

March 7, 2024 | globenewswire.com

Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial

February 26, 2024 | globenewswire.com

Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference

February 11, 2024 | benzinga.com

Xtant Medical Hldgs Stock (AMEX:XTNT) Dividends: History, Yield and Dates

January 1, 2024 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on Xtant Medical Holdings (XTNT)

December 6, 2023 | msn.com

BTIG Initiates Coverage of Xtant Medical Holdings (XTNT) with Buy Recommendation

November 27, 2023 | msn.com

Xtant Medical Holdings (XTNT) Price Target Increased by 37.04% to 1.89

November 24, 2023 | morningstar.com

Xtant Medical Holdings Inc XTNT

November 20, 2023 | msn.com

Xtant Medical says chief commercial officer Brandt buys 41.7K shares in co

November 10, 2023 | finance.yahoo.com

Q3 2023 Xtant Medical Holdings Inc Earnings Call

November 9, 2023 | finance.yahoo.com

Xtant Medical to Participate in Upcoming Investor Conferences

November 9, 2023 | msn.com

Xtant Medical GAAP EPS of $0.07 beats by $0.09, revenue of $25.02M beats by $6.12M

November 9, 2023 | finance.yahoo.com

Xtant Medical Announces Record Third Quarter Revenue of $25 Million

November 9, 2023 | finance.yahoo.com

Xtant Medical Holdings Inc (XTNT) Reports Record Q3 Revenue and Raises 2023 Guidance

November 2, 2023 | finance.yahoo.com

Xtant Medical to Issue Third Quarter 2023 Financial Results on November 9, 2023

October 24, 2023 | finanznachrichten.de

Xtant Medical, Inc.: Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical

See More Headlines

Receive XTNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xtant Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/24/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:XTNT
Previous Symbol: AMEX:XTNT
CUSIP: N/A
CIK: 1453593
Web: xtantmedical.com
Phone: (406) 388-0480
Fax: 406-388-1354
Employees: 134
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.60
High Stock Price Target: $2.00
Low Stock Price Target: $1.20
Potential Upside/Downside: +84.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $660,000.00
Net Margins: 0.72%
Pretax Margin: -1.14%
Return on Equity: 1.56%
Return on Assets: 0.84%

Debt

Debt-to-Equity Ratio: 0.34
Current Ratio: 2.82
Quick Ratio: 1.22

Sales & Book Value

Annual Sales: $91.30 million
Price / Sales: 1.23
Cash Flow: $0.03 per share
Price / Cash Flow: 26.62
Book Value: $0.39 per share
Price / Book: 2.22

Miscellaneous

Outstanding Shares: 130,220,000
Free Float: 117,456,000
Market Cap: $112.65 million
Optionable: Not Optionable
Beta: 0.22

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Sean E. Browne (Age 58)
President, CEO & Director
Comp: $1.06M
Mr. Scott C. Neils (Age 40)
Chief Financial Officer
Comp: $517.86k
Mr. Kevin D. Brandt (Age 58)
Senior VP & Chief Commercial Officer
Comp: $565.25k
Mr. Mark A. Schallenberger (Age 38)
Chief Operations Officer
Ms. Catherine Lundy
Vice President of Human Resources

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

XTNT Stock Analysis - Frequently Asked Questions

Should I buy or sell Xtant Medical stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xtant Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XTNT shares.
View XTNT analyst ratings or view top-rated stocks.
What is Xtant Medical's stock price target for 2024?: 2 Wall Street analysts have issued twelve-month price targets for Xtant Medical's shares. Their XTNT share price targets range from $1.20 to $2.00. On average, they predict the company's stock price to reach $1.60 in the next year. This suggests a possible upside of 91.2% from the stock's current price.
View analysts price targets for XTNT or view top-rated stocks among Wall Street analysts.
Are investors shorting Xtant Medical?: Xtant Medical saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 280,600 shares, an increase of 45.8% from the March 15th total of 192,500 shares. Based on an average daily trading volume, of 145,100 shares, the short-interest ratio is currently 1.9 days. Currently, 0.6% of the shares of the company are short sold.
View Xtant Medical's Short Interest.
When is Xtant Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our XTNT earnings forecast.
How were Xtant Medical's earnings last quarter?: Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) released its earnings results on Wednesday, February, 24th. The medical device company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.11. The medical device company had revenue of $14.02 million for the quarter. Xtant Medical had a net margin of 0.72% and a trailing twelve-month return on equity of 1.56%.

When did Xtant Medical's stock split?: Shares of Xtant Medical reverse split before market open on Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What guidance has Xtant Medical issued on next quarter's earnings?: Xtant Medical issued an update on its FY 2024 earnings guidance on Monday, April, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $112.0 million-$116.0 million, compared to the consensus revenue estimate of $115.9 million.
What other stocks do shareholders of Xtant Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Xtant Medical investors own include Aurinia Pharmaceuticals (AUPH), LadRx (CYTR), Heat Biologics (HTBX), Neovasc (NVCN), Rexahn Pharmaceuticals (REXN), Biopharmx (BPMX), Adamis Pharmaceuticals (ADMP), Lipocine (LPCN) and Synergy Pharmaceuticals (SGYP).
How do I buy shares of Xtant Medical?: Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:XTNT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Xtant Medical (XTNT) Stock Price, News & Analysis

Xtant Medical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Xtant Medical Stock (NYSEAMERICAN:XTNT)

XTNT Stock Price History

XTNT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

XTNT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™